Skip to main
ENLV
ENLV logo

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd is poised for a positive outlook due to the promising interim results from its Phase I/II trial of Allocetra, which demonstrated a statistically significant 47.0% reduction in pain and notable improvements in joint function and stiffness among patients with knee osteoarthritis. The six-month data highlights the therapy's sustained efficacy, with an 83% patient response rate, further indicating its potential as a durable treatment option that addresses disease progression rather than merely providing symptomatic relief. Additionally, the favorable safety profile, with no serious adverse events reported, strengthens the case for Allocetra's further development and enhances the company's positioning for future strategic partnerships in a market with substantial unmet medical needs.

Bears say

Enlivex Therapeutics Ltd faces significant financial challenges, including a limited cash runway that raises concerns about its ability to fund ongoing clinical trials and operational expenses. The company has not yet generated any significant revenue from its immunotherapy product, Allocetra, which may hinder its ability to attract necessary investment for further development. Additionally, the high cost of regulatory compliance and the competitive biopharmaceutical landscape contribute to uncertainties surrounding the successful commercialization of its drug pipeline.

ENLV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ENLV has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.